Bloodstream infections and central line-associated bloodstream infections

• Published in: The Surgical clinics of North America Vol. 94; no. 6; p. 1233
• Main Authors: Watson, Christopher M, Al-Hasan, Majdi N
• Format: Journal Article
• Language: English
• Published: United States 01.12.2014
• Subjects: Anti-Bacterial Agents - therapeutic use; Bacteremia - diagnosis; Bacteremia - drug therapy; Bacteremia - etiology; Bacteremia - prevention & control; Catheter-Related Infections - diagnosis; Catheter-Related Infections - drug therapy; Catheter-Related Infections - etiology; Catheter-Related Infections - prevention & control; Cross Infection - diagnosis; Cross Infection - drug therapy; Cross Infection - etiology; Cross Infection - prevention & control; Humans; Infection Control - methods; Postoperative Complications - diagnosis; Postoperative Complications - drug therapy; Postoperative Complications - prevention & control; Bloodstream infection(s); Septicemia; Bacteremia; Catheter-related bloodstream infection(s)

It is estimated that more than 575,000 individuals develop bloodstream infections (BSI) annually in North America, accounting for nearly 80,000 deaths. Central line-associated BSI (CLABSI) is a major contributor to the cost of health care. Although primary BSI may be seen by the surgeon, a secondary...